Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1030521 | 0.85 | ACHE (0.46) | ESR2NR1H2ACHEMAPK1 | |
| SCHEMBL1030522 | 0.85 | ACHE (0.46) | ESR2NR1H2ACHEMAPK1 | |
| SCHEMBL25625337 | 0.85 | MAPK1 (0.50) | GPR119ESR2NR1H2ACHEMAPK1 | |
| SCHEMBL16113475 | 0.82 | GPR119 (0.53) | GPR119ESR2NR1H2EGLN2AR | |
| SCHEMBL12266171 | 0.79 | ACHE (0.44) | ESR2NR1H2ACHEMAPK1 | |
| SCHEMBL2397980 | 0.79 | ACHE (0.44) | ESR2NR1H2ACHEMAPK1 | |
| SCHEMBL23464183 | 0.77 | GPR119 (0.47) | GPR119EGLN2MAPK1ARJAK2 | |
| SCHEMBL21344400 | 0.77 | GPR119 (0.43) | GPR119EGLN2MAPK1ARJAK2 | |
| SCHEMBL21343950 | 0.76 | ACHE (0.43) | ACHEMIF | |
| SCHEMBL23464517 | 0.75 | GPR119 (0.44) | GPR119EGLN2MAPK1ARJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399262-A1 | COMPOUNDS FOR INHIBITING PROTEIN DEGRADATION AND METHODS OF USE THEREOF IN THE TREATMENT OF CANCER | PI THERAPEUTICS LTD (IL) | 2020-12-24 | — | — | US | disclosed |
| WO-2019171379-A1 | COMPOUNDS FOR INHIBITING PROTEIN DEGRADATION AND METHODS OF USE THEREOF IN THE TREATMENT OF CANCER | PI THERAPEUTICS LTD. (IL) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399262-A1 | COMPOUNDS FOR INHIBITING PROTEIN DEGRADATION AND METHODS OF USE THEREOF IN THE TREATMENT OF CANCER | ATG7, SQSTM1, UBQLN1 | GPR119 3596/4885ESR2 2232/4885NR1H2 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.